Get in Touch

A New Prescription Nasal Spray Providing Hope to Dementia Patients and their Carers

Presenting at Sachs 3rd Neurosciences Innovation Forum Sunday, January 12, 2020 at 12:05 PM Marines' Memorial Club in San Francisco, California
Presenting at Biotech Showcase Tuesday January 14, 2020 9:30 AM Hilton San Francisco Union Square in San Francisco, California.


SAN FRANCISCO, Jan. 9, 2020 – LACHESIS BIOSCIENCES LTD, a clinical-stage biotechnology company targeting dementia caused by Alzheimer’s and Parkinson’s disease, announced today that its chief executive officer, Dr. Tim Morgan, will present at the Biotech Showcase 2020 conference being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California. 

General presentation information: Lachesis is developing a patented rivastigmine nasal spray candidate that’s low-risk, with high-return potential. Our presentation includes positive clinical and usability data, future-plans and emphasizes why you should trust us to advance dementia treatment. We make it easier for patients to take higher doses of this important dementia medication.

About LACHESIS BIOSCIENCES

A clinical-stage biotechnology company using its patented, nasal drug delivery technology to advance treatments for dementia and agitation associated with Alzheimer’s and Parkinson’s disease.

Key Takeaways
  • Targeting Alzheimer’s Disease with a Proven Mechanism of Action.
  • 2 assigned patents for LBIO-R32 Offering Improved Tolerability vs. Existing Formulation of Rivastigmine.
  • Expedited Path to Market with a significantly De-risked Asset.
Media Gallery
Files
Related Bios
Dr Timothy Morgan
Chief Executive Officer and Managing Director, Founder
View Full Bio>>
Mr Christian Nicks
Non-Executive Chairman
View Full Bio>>
Dr Amanda Reese
Non-Executive Director
View Full Bio>>
Contacts
Tim Morgan
tim.morgan@lachesisbio.com.au
+61 418 138 877
Chief Executive Officer